Adaptimmune Therapeutics plc (NASDAQ:ADAP) Receives $2.18 Average PT from Analysts
Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average […]
Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average […]
